Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Abstract

Immune checkpoint inhibitors (ICIs) have exhibited promising efficacy in non-small cell lung cancer (NSCLC), but the response occurs in only a minority of patients. In clinic, biomarkers such as TMB (tumor mutation burden) and PD-L1 (programmed cell death 1 ligand 1) still have their limitations in predicting the prognosis of ICI treatment. Hence, reliable predictive markers for ICIs are urgently needed. A public immunotherapy dataset with clinical information and mutational data of 75 NSCLC patients was obtained from cBioPortal as the discovery cohort, and another immunotherapy dataset of 249 patients across multiple cancer types was collected as the validation. Integrated bioinformatics analysis was performed to explore the potential mechanism, and immunohistochemistry studies were used to verify it. <i>AHNAK</i> nucleoprotein 2 (<i>AHNAK2</i>) was reported to have pro-tumor growth effects across multiple cancers, while its role in tumor immunity was unclear. We found that approximately 11% of the NSCLC patients harbored <i>AHNAK2</i> mutations, which were associated with promising outcomes to ICI treatments (ORR, p = 0.013). We further found that <i>AHNAK2</i> deleterious mutation (del-<i>AHNAK2</i> ^mut) possessed better predictive function in NSCLC than non-deleterious <i>AHNAK2</i> mutation (PFS, OS, log-rank p < 0.05), potentially associated with stronger tumor immunogenicity and an activated immune microenvironment. This work identified del-<i>AHNAK2</i> ^mut as a novel biomarker to predict favorable ICI response in NSCLC.